JASPER study-switch

Japan post-marketing study of Peficitinib use in RA patients study-switch

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031220112

Enrollment

100

Registered

2022-06-04

Start date

2022-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who provided written informed consent to study participation 2. Patients aged 20 years old and older as of the index date 3. RA patients switched from bDMARDs (anti-TNF antibody, TNFR-Ig, anti-IL-6R antibody, or CTLA4-Ig) to Peficitinib due to inadequate response* to bDMARDs. (switching from bDMARD to peficitinib must be within 60 days) 4. Patients who are registered to Peficitinib PMS (SMR001) 5. Patients who have been followed up for at least 24 weeks from the start of Peficitinib administration*** (including those who are discontinued before 24 weeks from the start of Peficitinib administration) *: Use of one or more bDMARDs for at least 12 weeks as prior therapy and disease activity at Index date has not reached remission/LDA (DAS-ESR < 3.2)

Exclusion criteria

Exclusion criteria: 1. Patients who were administered Peficitinib for diseases other than RA 2. Patients who were administered JAK inhibitors (including Peficitinib) for RA treatment before the index date 3. Patients who were administered Peficitinib 50 mg despite of not having moderate or more severe hepatic impairment from the index date to 24 weeks after the index date

Design outcomes

Primary

Measure	Time frame
The change in DAS28-ESR from the index date to 24 weeks	—

Secondary

Measure	Time frame
1) Adverse drug reactions after being switched from bDMARDs to Peficitinib 2) The changes in DAS28-ESR from the index date to 4 and 12 weeks 3) The evidence of remission/low disease activity (LDA) in DAS28-ESR at 4, 12 and 24 weeks (DAS28-ESR < 3.2) 4) DAS28-ESR improvement based on assessment by EULAR improvement criteria at 4, 12 and 24 weeks 5) The change in DAS28-CRP from the index date to 4, 12 and 24 weeks 6) The evidence of remission/LDA in DAS28-CRP at 4, 12 and 24 weeks (DAS28-CRP < 3.2) 7) The change in SDAI from the index date to 4, 12 and 24 weeks 8) The evidence of remission/LDA in SDAI at 4, 12 and 24 weeks (SDAI =<11) 9) The change in CDAI from the index date to 4, 12 and 24 weeks 10) The evidence of remission/LDA in CDAI at 4, 12 and 24 weeks (CDAI =<10)	—

Measure

Time frame

1) Adverse drug reactions after being switched from bDMARDs to Peficitinib 2) The changes in DAS28-ESR from the index date to 4 and 12 weeks 3) The evidence of remission/low disease activity (LDA) in DAS28-ESR at 4, 12 and 24 weeks (DAS28-ESR < 3.2) 4) DAS28-ESR improvement based on assessment by EULAR improvement criteria at 4, 12 and 24 weeks 5) The change in DAS28-CRP from the index date to 4, 12 and 24 weeks 6) The evidence of remission/LDA in DAS28-CRP at 4, 12 and 24 weeks (DAS28-CRP < 3.2) 7) The change in SDAI from the index date to 4, 12 and 24 weeks 8) The evidence of remission/LDA in SDAI at 4, 12 and 24 weeks (SDAI =<11) 9) The change in CDAI from the index date to 4, 12 and 24 weeks 10) The evidence of remission/LDA in CDAI at 4, 12 and 24 weeks (CDAI =<10)

—

Contacts

Public ContactKunihiro Yamaoka

Kitasato University Hospital

FY20-2007@tri-kobe.org+81-42-778-8111

Outcome results